Zealand Pharma Expands U.S. Footprint with Cambridge Research Hub — Zealand Pharma A/S

Event summary

Zealand Pharma will establish a new research hub in Cambridge, Massachusetts, operational from September 2026.
The facility will focus on AI-driven drug discovery, advanced automation, and next-generation molecule creation.
Cambridge hub will expand Zealand Pharma’s research platform beyond peptides to include hybrid modalities like antibody-peptide conjugates (APCs) and siRNAs.
The site is located at 35 Cambridgepark Drive, a purpose-built lab property owned by Healthpeak.
Zealand Pharma is actively recruiting talent for the new Cambridge location.

The big picture

Zealand Pharma’s new Cambridge research hub underscores the company’s strategic shift towards leveraging AI and advanced technologies to expand its drug discovery capabilities. This move aligns with broader industry trends of biotech firms establishing research hubs in innovation hotspots like Cambridge to tap into world-class talent and cutting-edge technologies. The expansion also reflects Zealand Pharma’s ambition to become a leader in obesity and metabolic health, competing with other biotech firms investing heavily in similar areas.

What we're watching

Execution Risk: Whether Zealand Pharma can successfully integrate AI and automation into its drug discovery process to accelerate medicine creation.
Talent Acquisition: The pace at which Zealand Pharma can attract and retain top talent in the competitive Cambridge biotech ecosystem.
Strategic Expansion: How the Cambridge hub will enhance Zealand Pharma’s ability to develop and commercialize innovative medicines for obesity and metabolic health.